



-30-

What is claimed is:

1. A method of treating migraine comprising administering to a patient in need thereof an effective amount of a selective iGluR₅ receptor antagonist or a pharmaceutically acceptable salt thereof.
2. A method of treating migraine comprising administering to a patient in need thereof a pharmaceutical composition comprising a selective iGluR₅ receptor antagonist in combination with one or more pharmaceutically acceptable carriers, diluents, or excipients.
3. The method according to Claim 1 wherein the selective iGluR₅ receptor antagonist is 3S, 4aR, 6S, 8aR-6-(((4-carboxy) phenyl) methyl) -1, 2, 3, 4, 4a, 5, 6, 7, 8, 8a -decahydroisoquinoline-3-carboxylic acid.
4. The method according to Claim 1 wherein the selective iGluR₅ receptor antagonist is 3S, 4aR, 6S, 8aR-6-(((1H-Tetrazole-5-yl) methyl) oxy) methyl) -1, 2, 3, 4, 4a, 5, 6, 7, 8, 8a-decahydroisoquinoline-3-carboxylic acid.
5. The method according to Claim 1 wherein the selective iGluR₅ receptor antagonist is given by the formula



6. The method according to Claim 1 wherein the selective iGluR₅ receptor antagonist is a compound of the formula



-31-

wherein R¹ and R² are each independently H, C₁-C₂₀ alkyl, C₂-C₆ alkenyl, C₁-C₆ alkylaryl, C₁-C₆ alkyl(C₃-C₁₀)cycloalkyl, C₁-C₆ alkyl-N,N-C₁-C₆ dialkylamine, C₁-C₆ alkyl-pyrrolidine, C₁-C₆ alkyl-piperidine, C₁-C₆ alkyl-morpholine or a pharmaceutically acceptable salt thereof.

5

7. The method according to Claim 6 wherein the selective iGluR₅ receptor antagonist is selected from 3S, 4aR, 6S, 8aR Ethyl 6-(((2S)-2-(Ethoxycarbonyl)-4,4-difluoropyrrolidinyl)methyl)-1, 2, 3, 4, 4a, 5, 6, 7, 8, 8a-decahydroisoquinoline-3-carboxylate, or 3S, 4aR, 6S, 8aR 6-(((2S)-2-(Carboxylic acid)-4,4-difluoropyrrolidinyl)methyl)-1, 2, 3, 4, 4a, 5, 6, 7, 8, 8a-decahydroisoquinoline-3-carboxylic Acid

10

8. A method of treating dural protein extravasation comprising administering to a patient in need thereof an effective amount of a selective iGluR₅ receptor antagonist.

15

9. A method of treating migraine comprising administering to a patient in need thereof an effective amount of a compound, or combination thereof, which possesses the activity of a selective iGluR₅ receptor antagonist.

20

10. The use of a selective iGluR₅ receptor antagonist for the manufacture of a medicament for treating migraine.

25


11. The use according to Claim 10 wherein the selective iGluR₅ receptor antagonist is 3S, 4aR, 6S, 8aR-6-(((4-carboxy) phenyl) methyl) -1, 2, 3, 4, 4a, 5, 6, 7, 8, 8a - decahydroisoquinoline-3-carboxylic acid.

30


12. The use according to Claim 10 wherein the selective iGluR₅ receptor antagonist is 3S, 4aR, 6S, 8aR-6-(((1H-Tetrazole-5-yl) methyl) oxy) methyl) - 1, 2, 3, 4, 4a, 5, 6, 7, 8, 8a-decahydroisoquinoline-3-carboxylic acid.

13. The use according to Claim 10 wherein the selective iGluR₅ receptor antagonist is given by the formula


-32-



14. The use according to Claim 10 wherein the selective iGluR₅ receptor antagonist is
5 a compound of Formula I



- 10 wherein R¹ and R² are each independently H, C₁-C₂₀ alkyl, C₂-C₆ alkenyl, C₁-C₆
alkylaryl, C₁-C₆ alkyl(C₃-C₁₀)cycloalkyl, C₁-C₆ alkyl-N,N-C₁-C₆ dialkylamine, C₁-C₆
alkyl-pyrrolidine, C₁-C₆ alkyl-piperidine, or C₁-C₆ alkyl-morpholine; or a
pharmaceutically acceptable salt thereof.
- 15 15. The use according to Claim 14 wherein the selective iGluR₅ receptor antagonist is
selected from 3S, 4aR, 6S, 8aR Ethyl 6-(((2S)-2-(Ethoxycarbonyl)-4,4-
difluoropyrrolidinyl)methyl)-1, 2, 3, 4, 4a, 5, 6, 7, 8, 8a-decahydroisoquinoline-3-
carboxylate, or 3S, 4aR, 6S, 8aR 6-(((2S)-2-(Carboxylic acid)-4,4-
difluoropyrrolidinyl)methyl)-1, 2, 3, 4, 4a, 5, 6, 7, 8, 8a-decahydroisoquinoline-3-
20 carboxylic Acid
16. A compound of the formula



-33-

wherein R¹ and R² are each independently H, C₁-C₂₀ alkyl, C₂-C₆ alkenyl, C₁-C₆ alkylaryl, C₁-C₆ alkyl(C₃-C₁₀)cycloalkyl, C₁-C₆ alkyl-N,N-C₁-C₆ dialkylamine, C₁-C₆ alkyl-pyrrolidine, C₁-C₆ alkyl-piperidine, C₁-C₆ alkyl-morpholine or a pharmaceutically acceptable salt thereof.

5

17. A compound according to Claim 16 wherein R¹ and R² are each independently H or C₁-C₂₀ alkyl.

10

18. A compound which is 3S, 4aR, 6S, 8aR Ethyl 6-(((2S)-2-(Ethoxycarbonyl)-4,4-difluoropyrrolidinyl)methyl)-1, 2, 3, 4, 4a, 5, 6, 7, 8, 8a-decahydroisoquinoline-3-carboxylate, or a pharmaceutically acceptable salt thereof.

15

19. A compound which is 3S, 4aR, 6S, 8aR 6-(((2S)-2-(Carboxylic acid)-4,4-difluoropyrrolidinyl)methyl)-1, 2, 3, 4, 4a, 5, 6, 7, 8, 8a-decahydroisoquinoline-3-carboxylic acid, or a pharmaceutically acceptable salt thereof.

20

20. A pharmaceutical composition which comprises a compound as claimed in Claim 16 in combination with one or more pharmaceutically acceptable carriers, diluents, or excipients.

21. A pharmaceutical composition for the treatment of migraine which comprises a selective iGluR₅ receptor antagonist in combination with a pharmaceutically acceptable carrier, diluent, or excipient.

25

22. A compound which is 3S, 4aR, 6S, 8aR Ethyl 6-(((2S)-2-(Ethoxycarbonyl)-4,4-difluoropyrrolidinyl)methyl)-1, 2, 3, 4, 4a, 5, 6, 7, 8, 8a-decahydroisoquinoline-3-carboxylate•mandelate.